Premium
Intestinal cancer in patients with Crohn's disease: A systematic review and meta‐analysis
Author(s) -
Uchino Motoi,
Ikeuchi Hiroki,
Hata Keisuke,
Minagawa Tomohiro,
Horio Yuki,
Kuwahara Ryuichi,
Nakamura Shiro,
Watanabe Kenji,
Saruta Masayuki,
Fujii Toshimitsu,
Kobayashi Taku,
Sugimoto Ken,
Hirai Fumihito,
Esaki Motohiro,
Hiraoka Sakiko,
Matsuoka Katsuyoshi,
Shinzaki Shinichiro,
Matsuura Minoru,
Inoue Nagamu,
Nakase Hiroshi,
Watanabe Mamoru
Publication year - 2021
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.15229
Subject(s) - medicine , colorectal cancer , colonoscopy , meta analysis , cancer , incidence (geometry) , disease , anal cancer , systematic review , medline , crohn's disease , oncology , physics , political science , law , optics
Background and Aim Although surveillance colonoscopy is recommended by several guidelines for Crohn's disease (CD), the evidence is insufficient to support the validity of this recommendation. Moreover, the efficacy of surveillance colonoscopy for anorectal cancer remains unclear. Therefore, we performed a systematic review of cancer in patients with CD before considering the proper surveillance methods. Methods We conducted a systematic review and meta‐analysis examining the incidence of intestinal cancer and a literature review to clarify the characteristic features of cancer in CD. We performed the systematic literature review of studies published up to May 2019. Results Overall, 7344 patients were included in eight studies. The standardized incidence ratios (95% confidence intervals) of colorectal cancer (CRC) and small bowel cancer (SBC) were 2.08 (1.43–3.02) and 22.01 (9.10–53.25), respectively. The prevalence of CRC and SBC was 57/7344 (0.77%) and 17/7344 (0.23%), respectively, during a median follow‐up of 12.55 years. Additionally, 54 studies reporting 208 anorectal cancer cases were identified. In patients with anorectal cancer, the prognosis for survival was 2.1 ± 2.3 years, and advanced cancer greater than stage T3 occurred in 46/74 patients (62.1%). Many more reports of anorectal cancer were published in Asia than in Western countries. Conclusion Although we were unable to state a recommendation for surveillance for SBC, we should perform cancer surveillance for CRC in patients with CD. However, the characteristics of cancer may differ according to geography or race. We must establish proper and effective surveillance methods that are independently suitable to detect these differences.